Conclusions: Our findings showed that the intestinal activation of LXRα and a parallel induction of hepatic SRB1 are protective against inflammation, steatosis, and advanced liver fibrosis in MASLD. This evidence concerns the gene SCARB1 and metabolic dysfunction-associated steatotic liver disease.